You are here

Article Text

Article menu
Download PDFPDF
PostScript
Correspondence
Diagnostic caveats of immunoreactivity for Ki67 and chromogranin A in hyalinizing trabecular tumour of the thyroid
  1. Ho Sung Park1,
  2. Kyoung Min Kim1,
  3. Jun Sang Bae1,
  4. Myoung Ja Chung1,
  5. Ho Lee2,
  6. Woo Sung Moon1,
  7. Kyu Yun Jang1
  1. 1 Department of Pathology, Chonbuk National University Medical School, Research Institute of Clinical Medicine and Research Institute for Endocrine Sciences, Jeonju, Republic of Korea
  2. 2 Forensic Medicine, Chonbuk National University Medical School, Research Institute of Clinical Medicine and Research Institute for Endocrine Sciences, Jeonju, Republic of Korea
  1. Correspondence to Dr Kyu Yun Jang, Department of Pathology, Chonbuk National University Medical School, San 2-20 Keumam-dong, Dukjin-gu, Jeonju 561-180, Republic of Korea; kyjang{at}chonbuk.ac.kr

https://doi.org/10.1136/jclinpath-2014-202339

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Hyalinizing trabecular tumour (HTT) of the thyroid is a rare tumour having a prominent trabecular growth pattern and stromal hyalinisation.1 ,2 However, these histologic features can be seen in other thyroid tumours, such as follicular neoplasm, follicular variant of papillary thyroid carcinoma (PTC), medullary thyroid carcinoma (MTC), and primary thyroid paraganglioma.3 ,4 Therefore, HTT should be differentially diagnosed from these other tumour types. When making a diagnosis of HTT, the expression of Ki67 in the cell membrane could be helpful. Principally, Ki67 is used to assess the proportion of a given tumour population that is growing and could be used for the diagnosis or grading of malignant tumours.5 ,6 However, in HTT, Ki67 is characteristically expressed in the cell membrane but not in the nuclei of the tumour cells.7 ,8 Therefore, we evaluated the expression of Ki67 in eight cases of HTT with two types of automated immunohistochemical staining (IHC) systems and a manual method.

    This study obtained Institutional Review Board approval, and informed consent was obtained according to the Declaration of Helsinki. Eight cases of HTT and two control cases of MTC were used for this study. The histologic sections were made from the largest cross-sectional area of the tumour, and the IHC was performed with the serially sectioned histologic slides. Antibodies against thyroglobulin, thyroid transcription factor 1 (TTF-1), cytokeratin 19 (CK19), high-molecular weight cytokeratin (HMW-CK), galectin-3, chromogranin A (CgA), synaptophysin, calcitonin, thyroglobulin (TG), and Ki67 were used in the staining processes of a fully automated IHC system with the BOND …

    View Full Text

    Footnotes

    • Contributors Study design: HSP, MJC, HL, WSM, and KYJ. Data acquisition: HSP, KMK, JSB, and KYJ. Immunohistochemical staining: KMK and JSB. Data Interpretation: HSP, MJC, HL, WSM, and KYJ. Writing and final approval of manuscript: HSP, KMK, JSB, MJC, HL, WSM, and KYJ.

    • Funding This work was supported by research funds of Chonbuk National University in 2012, and by the National Research Foundation of Korea Grant funded by the Korean Government (No. 2012-0009320).

    • Competing interests None.

    • Patient consent Obtained.

    • Ethics approval This study obtained Chonbuk National University Institutional Review Board approval (IRB No., CUH 2013-04-026-001).

    • Provenance and peer review Not commissioned; externally peer reviewed.